Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
NOVN:SWX
Novartis AG
CHF 116.28
0.00%
(0.00) 1D
Apr 23, 5:30:19 PM GMT+2  ·   CHF
All symbols
SymbolPriceChange% Change
Generating top insights for NOVN...
Mkt. cap
237.82B
Avg. vol.
2.91M
Volume
0.00
Dividend
3.18%
Quarterly dividend
CHF 0.93
Ex dividend date
Mar 10, 2026
P/E ratio
20.71
52-wk high
CHF 131.00
52-wk low
CHF 87.89
EPS
CHF 5.61
Shares outstanding
2.03B
No. of employees
75K
News stories
From sources across the web
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3K
FoundedFeb 29, 1996
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websitenovartis.com
Last report
Feb 4, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
2.03/ (2.07 est.)USD
-1.73%miss
Revenue / Estimate
13.86B/ (14.08B est.)USD
-1.54%miss
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
13.62B
14.84B
14.36B
13.86B
Cost of goods sold
3.22B
3.32B
3.54B
3.54B
Cost of revenue
3.22B
3.32B
3.54B
3.54B
Research and development expenses
2.37B
2.62B
2.86B
2.84B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.06B
3.44B
3.30B
3.44B
Operating expense
5.58B
6.05B
6.24B
6.46B
Total operating expenses
8.80B
9.37B
9.77B
10.00B
Operating income
4.82B
5.46B
4.58B
3.86B
Other non operating income
46.00M
-13.00M
-7.00M
-130.00M
EBT including unusual items
4.41B
4.53B
4.20B
3.22B
EBT excluding unusual items
4.59B
5.16B
4.29B
3.49B
Income tax expense
798.00M
507.00M
266.00M
814.00M
Effective tax rate
18.11%
11.19%
6.34%
25.30%
Other operating expenses
148.00M
-4.00M
70.00M
190.00M
Net income
3.61B
4.04B
3.93B
2.41B
Net profit margin
26.48%
27.24%
27.36%
17.38%
Earnings per share
2.28
2.42
2.25
2.03
Interest and investment income
-
-
-
373.00M
Interest expense
-270.00M
-289.00M
-281.00M
-304.00M
Net interest expenses
-270.00M
-289.00M
-281.00M
69.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.91B
6.56B
5.78B
4.96B
Gain or loss from assets sale
22.00M
-67.00M
81.00M
80.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer